Marex Group’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Marex Group’s Portfolio KTTAW Stock Details KTTAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$250	Hold	25,000	–	–	﹤0.01%	1004
2025 Q4	$345	Hold	25,000	–	–	﹤0.01%	961
2025 Q3	$423	Hold	25,000	–	–	﹤0.01%	838
2025 Q2	$388	Hold	25,000	–	–	﹤0.01%	641
2025 Q1	$460	Hold	25,000	–	–	﹤0.01%	682
2024 Q4	$925	Hold	25,000	–	–	﹤0.01%	675
2024 Q3	$873	Hold	25,000	–	–	﹤0.01%	604
2024 Q2	$275	Hold	25,000	–	–	﹤0.01%	635
2024 Q1	$308	Hold	25,000	–	–	﹤0.01%	478
2023 Q4	$450	Buy	+25,000	New	+$300	﹤0.01%	560

Other funds holding KTTAW

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Marex Group's KTTAW Position: Q1 2026 in Review

Marex Group held its Pasithea Therapeutics Warrants (KTTAW) position steady in Q1 2026 at 25,000 shares worth $250. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

Marex Group first reported a position in KTTAW in Q4 2023 and has held it in 10 quarters since. The position peaked at $925 in Q4 2024. 5 funds tracked by Wall St. Rank hold KTTAW as of Q1 2026.

Marex Group held 25,000 shares of Pasithea Therapeutics Warrants worth $250 as of Q1 2026.
Marex Group left its Pasithea Therapeutics Warrants share count unchanged in Q1 2026.
Pasithea Therapeutics Warrants made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #1004 holding.
Marex Group first reported a position in Pasithea Therapeutics Warrants in Q4 2023 and has held it in 10 quarters since.
Marex Group's Pasithea Therapeutics Warrants position peaked at $925 in Q4 2024.
5 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.